Gangadhar B N, Hofmann P, Karazman R, Probst C, Koinig G
National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Indien.
Wien Klin Wochenschr. 1996;108(4):101-4.
In this study 15 (4 males, 11 females) depressive patients (according to DSM-III-R criteria), who were refractory to psychopharmacological treatment were referred for electroconvulsive therapy (ECT). Six ECTs were administered within a period of 3 weeks. Before the first, third and fifth ECT and 15, 30, and 60 minutes after each of these 3 treatments serum levels of prolactin were determined. After six ECTs eight patients showed significant symptomatic improvement, whilst the depressive symptoms in the other seven patients remained more or less unchanged. There was no statistically significant difference with respect to prolactin response following the three ECTs between the symptomatically improved and the unchanged group. There was no correlation of severity of depression and prolactin baseline levels before the first ECT. Neither baseline prolactin levels prior to the first ECT nor prolactin response predicted therapeutic outcome. From this point of view changes in serum prolactin levels do not reflect therapeutic pathways in depression or mechanisms of action of ECT.
在本研究中,15名(4名男性,11名女性)抑郁患者(根据DSM-III-R标准)因对精神药物治疗无效而被转诊接受电休克治疗(ECT)。在3周内进行了6次ECT治疗。在第一次、第三次和第五次ECT治疗前以及这3次治疗每次后的15分钟、30分钟和60分钟测定血清催乳素水平。6次ECT治疗后,8名患者症状明显改善,而其他7名患者的抑郁症状或多或少未变。症状改善组和未改善组在3次ECT治疗后的催乳素反应方面无统计学显著差异。首次ECT治疗前抑郁严重程度与催乳素基线水平无相关性。首次ECT治疗前的催乳素基线水平和催乳素反应均不能预测治疗结果。从这一角度来看,血清催乳素水平的变化并不能反映抑郁症的治疗途径或ECT的作用机制。